Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical is moving forward with the proposed privatization of Shanghai Henlius Biotech through a merger by absorption. The company has dispatched a composite document outlining the merger details, including the expected timetable and recommendations from the Independent Board Committee. Shareholders are advised to review the terms and consider their options between the Cash Alternative and Share Alternative.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.